ArticlePDF Available

Synaptic Therapy in Alzheimer’s Disease: A CREB-centric Approach

  • January 2015
  • Journal of the American Society for Experimental NeuroTherapeutics 12(1)
DOI:10.1007/s13311-014-0327-5
Authors:
Andrew F Teich at Columbia University
Andrew F Teich
Russell E. Nicholls
Russell E. Nicholls
Russell E. Nicholls
  • This person is not on ResearchGate, or hasn't claimed this research yet.
Daniela Puzzo at University of Catania
Daniela Puzzo
Jole Fiorito at Columbia University
Jole Fiorito
Show all 7 authorsHide
Download full-text PDF
Read full-text
Download citation

Abstract

Therapeutic attempts to cure Alzheimer’s disease (AD) have failed, and new strategies are desperately needed. Motivated by this reality, many laboratories (including our own) have focused on synaptic dysfunction in AD because synaptic changes are highly correlated with the severity of clinical dementia. In particular, memory formation is accompanied by altered synaptic strength, and this phenomenon (and its dysfunction in AD) has been a recent focus for many laboratories. The molecule cyclic adenosine monophosphate response element-binding protein (CREB) is at a central converging point of pathways and mechanisms activated during the processes of synaptic strengthening and memory formation, as CREB phosphorylation leads to transcription of memory-associated genes. Disruption of these mechanisms in AD results in a reduction of CREB activation with accompanying memory impairment. Thus, it is likely that strategies aimed at these mechanisms will lead to future therapies for AD. In this review, we will summarize literature that investigates 5 possible therapeutic pathways for rescuing synaptic dysfunction in AD: 4 enzymatic pathways that lead to CREB phosphorylation (the cyclic adenosine monophosphate cascade, the serine/threonine kinases extracellular regulated kinases 1 and 2, the nitric oxide cascade, and the calpains), as well as histone acetyltransferases and histone deacetylases (2 enzymes that regulate the histone acetylation necessary for gene transcription).
Content uploaded by Daniela Puzzo
Author content
All content in this area was uploaded by Daniela Puzzo on Jan 19, 2016
Content may be subject to copyright.
Please wait...
If this message is not eventually replaced by the proper contents of the document, your PDF
viewer may not be able to display this type of document.
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by
visiting http://www.adobe.com/go/reader_download.
For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other
countries.
... Not surprisingly, reduction of AKT signaling is thought to play a role in the early cellular dysfunction associated with Aβ pathology, as it diminishes the aforementioned pro-survival responses [22]. With regards to ERK signaling, Aβ has been shown to interact with cell surface receptors, such as NMDA, mGluR5, and α7 nicotinic receptors leading to ERK phosphorylation [50]. The consequences of ERK activation in response to Aβ may depend on several factors including the mechanism by which ERK is activated, the cell type, the duration of ERK activation, and/or subcellular localization. ...
... The consequences of ERK activation in response to Aβ may depend on several factors including the mechanism by which ERK is activated, the cell type, the duration of ERK activation, and/or subcellular localization. It has been suggested that increased ERK activation in response to Aβ may represent a compensatory mechanism to counteract AD-related pathology [50]. In agreement with previous reports, we observed a significant increase in pERK after Aβ treatment, and fosgo-AM led to a further increase in pERK. ...
View
... It is a neurodegenerative disease characterized pathologically by amyloid beta (β) plaques and neurofibrillary tangles in the brain and clinically by the insidious onset of progressive dementia [2]. Amyloid beta (Aβ) and neurofibrillary tangles are the neuropathologic changes classically associated with AD; however, given the importance of synaptic plasticity and maintenance in learning and memory, synaptic dysfunction has been studied as a mechanism of dementia in AD and correlates with clinical dementia more closely than amyloid beta plaques or neurofibrillary tangles [3][4][5][6][7][8]. ...
... Since decreased CREB signaling in neurons is well described in AD, induces synaptic dysfunction, and has been implicated in the development of memory impairment [8], we examined the predicted effects of the differentially expressed miRNAs on this pathway ( Figure 2D). Downregulation of CREB signaling was predicted by the ad-sEVs isolated both from the CSF ( Figure 2D) and the serum (Supplementary Figure S2). ...
Adipocyte-Derived Small Extracellular Vesicles from Patients with Alzheimer Disease Carry miRNAs Predicted to Target the CREB Signaling Pathway in Neurons
Article
Full-text available
  • Sep 2023
  • INT J MOL SCI
Alzheimer disease (AD) is characterized by amyloid-β (Aβ) plaques, neurofibrillary tangles, synaptic dysfunction, and progressive dementia. Midlife obesity increases the risk of developing AD. Adipocyte-derived small extracellular vesicles (ad-sEVs) have been implicated as a mechanism in several obesity-related diseases. We hypothesized that ad-sEVs from patients with AD would contain miRNAs predicted to downregulate pathways involved in synaptic plasticity and memory formation. We isolated ad-sEVs from the serum and cerebrospinal fluid (CSF) of patients with AD and controls and compared miRNA expression profiles. We performed weighted gene co-expression network analysis (WGCNA) on differentially expressed miRNAs to identify highly interconnected clusters correlating with clinical traits. The WGCNA identified a module of differentially expressed miRNAs, in both the serum and CSF, that was inversely correlated with the Mini-Mental State Examination scores. Within this module, miRNAs that downregulate CREB signaling in neurons were highly represented. These results demonstrate that miRNAs carried by ad-sEVs in patients with AD may downregulate CREB signaling and provide a potential mechanistic link between midlife obesity and increased risk of AD.
View
... This observation inspired our experiments, and previous work 12 confirmed that the enhancement of CREB phosphorylation during memory formation was suppressed in animals exposed to oTau. CREB phosphorylation is a post-translational modification involved in gene transcription mechanisms leading to synaptic plasticity and memory formation and is likely to be affected in AD 13,14 . CREB is at the crossroads of several molecular pathways and mechanisms that have been proposed as potential therapeutic targets against AD, including the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) dependent protein kinases (PKG)/CREB pathway, the cAMP-dependent protein kinases (PKA)/CREB pathway and the mitogen activated protein kinase/ extracellular regulated kinase (MAPK/ERK) pathway 14 . ...
... CREB phosphorylation is a post-translational modification involved in gene transcription mechanisms leading to synaptic plasticity and memory formation and is likely to be affected in AD 13,14 . CREB is at the crossroads of several molecular pathways and mechanisms that have been proposed as potential therapeutic targets against AD, including the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) dependent protein kinases (PKG)/CREB pathway, the cAMP-dependent protein kinases (PKA)/CREB pathway and the mitogen activated protein kinase/ extracellular regulated kinase (MAPK/ERK) pathway 14 . The NO/cGMP/ PKG/CREB cascade is particularly attractive because of the availability of drugs boosting it, such as PDE5Is 12 . ...
Optimizing metabolic stability of phosphodiesterase 5 inhibitors: Discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity
Article
  • Jul 2023
  • BIOORG MED CHEM LETT
Phosphodiesterase 5 (PDE5) is a cyclic guanosine monophosphate-degrading enzyme involved in numerous biological pathways. Inhibitors of PDE5 are important therapeutics for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). We previously reported the first generation of quinoline-based PDE5 inhibitors for the treatment of AD. However, the short in vitro microsomal stability rendered them unsuitable drug candidates. Here we report a series of new quinoline-based PDE5 inhibitors. Among them, compound 4b, 8-cyclopropyl-3-(hydroxymethyl)-4-(((6-methoxypyridin-3-yl)methyl)amino)quinoline-6-carbonitrile, shows a PDE5 IC50 of 20nM and improved in vitro microsomal stability (t1/2=44.6min) as well as excellent efficacy in restoring long-term potentiation, a type of synaptic plasticity to underlie memory formation, in electrophysiology experiments with a mouse model of AD. These results provide an insight into the development of a new class of PDE5 inhibitors for the treatment of AD.
View
... Ca+2 dyshomeostasis has been linked to protein kinase A (PKA)/CREB pathway downregulation, according to reports (43) . For synaptic reorganization and memory formation, CREB phosphorylation by Ca2+/calmodulindependent protein kinase II (CaMKII) and PKA is necessary (44,45) . Here, CaMKII and PKA activation phosphorylates CREB at Ser133 to start BDNF transcription. ...
View
... In reality, blocking this receptor with a range of highly affine specific competitive antagonists, including ondansetron, tropisetron, granisetron, dolasetron, and others, has a number of advantageous therapeutic outcomes (33) . Over 200 genes, including those involved in the immunological response (36)(37) , inflammation (38) , differentiation, proliferation, cell survival, and apoptosis, are regulated by the transcription factor nuclear factor (NF)-κB (39,40) . This transcription factor's activation has been linked to the consequences of ionizing radiation exposure, and NF-κB is abnormally activated in many human disorders, including cancer and inflammatory conditions (36) . ...
Investigation of the neuroprotective effect of Granisetron through SV2A and 5-HT3 modulation in a radiation-induced brain injury rat model
Article
Full-text available
  • Jul 2023
Background: The development of neurotoxicity in healthy, non-targeted brain tissue exposed to radiation during cranial radiotherapy (RT) is the most frequent event of radiation-induced adverse effects. The 5-hydroxytryptamine-3 (5-HT3) receptor antagonists may also have a range of neuroprotective, anti-inflammatory, and antiphlogistic properties in addition to their anti-emetic effects. Materials and Methods: Study groups were formed in the following ways: Group 2: Irradiation (IR)- only (IR+Saline); Group 1: Normal control (orally fed control); Group 3: IR+Granisetron (IR+Granisetron): whole-brain IR and Granisetron 1 mg/kg/day (Merck) administered orally. 15 days of all therapies were given. The 15 days were completed with behavioral testing. In the entire brain IR-only (placebo) group, a substantial deterioration was seen in all studied marker levels and behavioral test results. Results: Compared to the IR-only group, all of these biochemical indicators significantly improved in the granisetron group (IR+Granisetron), and levels of the control group returned to normal. In behavioral test analyses, a substantial decline in the open field and passive avoidance learning social recognition tests was seen in the IR-only group compared to the healthy control group, whereas an improvement was seen in the IR+Granisetron group. In addition, the IR-only group showed a reduction in hippocampus neurons and Purkinje neurons as well as an increase in hippocampal gliosis, whereas the IR+Granisetron group showed an improvement and a return to the normal control group counts. Conclusion: In summary, we discovered that granisetron had neuroprotective properties in a rat model of radiation-induced brain damage.
View
5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy
Article
Full-text available
  • Apr 2024
Background Accumulation of tau in synapses in the early stages of Alzheimer’s disease (AD) has been shown to cause synaptic damage, synaptic loss, and the spread of tau pathology through trans-synaptically connected neurons. Moreover, synaptic loss correlates with a decline in cognitive function, providing an opportunity to investigate therapeutic strategies to target synapses and synaptic tau to rescue or prevent cognitive decline in AD. One of the promising synaptic targets is the 5-HT4 serotonergic receptor present postsynaptically in the brain structures involved in the memory processes. 5-HT4R stimulation exerts synaptogenic and pro-cognitive effects involving synapse-to-nucleus signaling essential for synaptic plasticity. However, it is not known whether 5-HT4R activation has a therapeutic effect on tau pathology. Methods The goal of this study was to investigate the impact of chronic stimulation of 5-HT4R by two agonists, prucalopride and RS-67333, in PS19 mice, a model of tauopathy. We utilized gradient assays to isolate pre- and post-synaptic compartments, followed by biochemical analyses for tau species and ubiquitinated proteins in the synaptic compartments and total brain tissue. Next, we performed kinetic assays to test the proteasome’s hydrolysis capacity in treatment conditions. Moreover, behavioral tests such as the open field and non-maternal nest-building tests were used to evaluate anxiety-like behaviors and hippocampal-related cognitive functioning in the treatment paradigm. Results Our results show that 5-HT4R agonism reduced tauopathy, reduced synaptic tau, increased proteasome activity, and improved cognitive functioning in PS19 mice. Our data suggest that enhanced proteasome activity by synaptic mediated signaling leads to the enhanced turnover of tau initially within synapses where the receptors are localized, and over time, the treatment attenuated the accumulation of tau aggregation and improved cognitive functioning of the PS19 mice. Conclusion Therefore, stimulation of 5-HT4R offers a promising therapy to rescue synapses from the accumulation of toxic synaptic tau, evident in the early stages of AD.
View
A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease
Article
  • Jan 2024
Alzheimer's disease (AD) is an onset and incurable neurodegenerative disorder that has been linked to various genetic, environmental, and lifestyle factors. Recent research has revealed several potential targets for drug development, such as the prevention of Aβ production and removal, prevention of tau hyperphosphorylation, and keeping neurons alive. Drugs that target numerous ADrelated variables have been developed, and early results are encouraging. This review provides a concise map of the different receptor signaling pathways associated with Alzheimer's Disease, as well as insight into drug design based on these pathways. It discusses the molecular mechanisms of AD pathogenesis, such as oxidative stress, aging, Aβ turnover, thiol groups, and mitochondrial activities, and their role in the disease. It also reviews the potential drug targets, in vivo active agents, and docking studies done in AD and provides prospects for future drug development. This review intends to provide more clarity on the molecular processes that occur in Alzheimer's patient's brains, which can be of use in diagnosing and preventing the condition.
View
ZCCHC17 Modulates Neuronal RNA Splicing and Supports Cognitive Resilience in Alzheimer's Disease
Article
  • Nov 2023
ZCCHC17 is a putative master regulator of synaptic gene dysfunction in Alzheimer's disease (AD), and ZCCHC17 protein declines early in AD brain tissue, before significant gliosis or neuronal loss. Here, we investigate the function of ZCCHC17 and its role in AD pathogenesis using data from human autopsy tissue (consisting of males and females) and female human cell lines. Co-immunoprecipitation (co-IP) of ZCCHC17 followed by mass spectrometry analysis in human iPSC-derived neurons reveals that ZCCHC17's binding partners are enriched for RNA-splicing proteins. ZCCHC17 knockdown results in widespread RNA-splicing changes that significantly overlap with splicing changes found in AD brain tissue, with synaptic genes commonly affected. ZCCHC17 expression correlates with cognitive resilience in AD patients, and we uncover an APOE4-dependent negative correlation of ZCCHC17 expression with tangle burden. Furthermore, a majority of ZCCHC17 interactors also co-IP with known tau interactors, and we find a significant overlap between alternatively spliced genes in ZCCHC17 knockdown and tau overexpression neurons. These results demonstrate ZCCHC17's role in neuronal RNA processing and its interaction with pathology and cognitive resilience in AD, and suggest that the maintenance of ZCCHC17 function may be a therapeutic strategy for preserving cognitive function in the setting of AD pathology.
View
View
S-Nitrosylation of CRTC1 in Alzheimer's disease impairs CREB-dependent gene expression induced by neuronal activity
Preprint
  • Aug 2023
CREB-regulated transcription coactivator 1 (CRTC1) plays an important role in synaptic plasticity, learning and long-term memory formation through regulation of neuronal activity-dependent gene expression, and CRTC1 dysregulation is implicated in Alzheimer's disease (AD). Here, we show that increased S-nitrosylation of CRTC1 (forming SNO-CRTC1), as seen in cell-based, animal-based, and human induced pluripotent stem cell (hiPSC)-derived cerebrocortical neuron-based AD models, disrupts its binding with CREB and diminishes the activity-dependent gene expression mediated by the CRTC1/CREB pathway. We identified Cys216 of CRTC1 as the primary target of S-nitrosylation by nitric oxide (NO)-related species. Using CRISPR/Cas9 techniques, we mutated Cys216 to Ala in hiPSC-derived cerebrocortical neurons bearing one allele of the APPSwe mutation (AD-hiPSC neurons). Introduction of this non-nitrosylatable CRTC1 construct rescued defects in AD-hiPSC neurons, including decreased neurite length and increased neuronal cell death. Additionally, expression of non-nitrosylatable CRTC1 in vivo in the hippocampus rescued synaptic plasticity in the form of long-term potentiation (LTP) in 5XFAD mice. Taken together, these results demonstrate that the formation of SNO-CRTC1 contributes to the pathogenesis of AD by attenuating the neuronal activity-dependent CREB transcriptional pathway, and suggests a novel therapeutic target for AD.
View
RAGE Inhibition in Microglia Prevents Ischemia-Dependent Synaptic Dysfunction in an Amyloid-Enriched Environment
Article
Full-text available
  • Jun 2014
Ischemia is known to increase the deleterious effect of β-amyloid (Aβ), contributing to early cognitive impairment in Alzheimer's disease. Here, we investigated whether transient ischemia may function as a trigger for Aβ-dependent synaptic impairment in the entorhinal cortex (EC), acting through specific cellular signaling. We found that synaptic depression induced by oxygen glucose deprivation (OGD) was enhanced in EC slices either in presence of synthetic oligomeric Aβ or in slices from mutant human amyloid precursor protein transgenic mice (mhAPP J20). OGD-induced synaptic depression was ameliorated by functional suppression of RAGE. In particular, overexpression of the dominant-negative form of RAGE targeted to microglia (DNMSR) protects against OGD-induced synaptic impairment in an amyloid-enriched environment, reducing the activation of stress-related kinases (p38MAPK and JNK) and the release of IL-1β. Our results demonstrate a prominent role for the RAGE-dependent neuroinflammatory pathway in the synaptic failure induced by Aβ and triggered by transient ischemia.
View
Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling
Article
Full-text available
  • May 2014
  • NEUROPSYCHOPHARMACOL
Memory consolidation is defined by the stabilization of a memory trace after acquisition, and consists of numerous molecular cascades that mediate synaptic plasticity. Commonly, a distinction is made between an early and a late consolidation phase, in which early refers to the first hours in which labile synaptic changes occur, whereas late consolidation relates to stable and long-lasting synaptic changes induced by de novo protein synthesis. How these phases are linked at a molecular level is not yet clear. Here we studied the interaction of the cyclic nucleotide-mediated pathways during the different phases of memory consolidation in rodents. In addition, the same pathways were studied in a model of neuronal plasticity, long-term potentiation (LTP). We demonstrated that cGMP/PKG signaling mediates early memory consolidation as well as early-phase-LTP, while cAMP/PKA signaling mediates late consolidation and late-phase-like LTP. Additionally, we show for the first time that early-phase cGMP/PKG-signaling requires late-phase cAMP/PKA-signaling in both LTP and long-term memory formation.Neuropsychopharmacology accepted article preview online, 12 May 2014; doi:10.1038/npp.2014.106.
View
Isolation and Characterization of E–64, a New Thiol Protease Inhibitor
Article
  • Mar 1978
A new thiol protease inhibitor, named E–64, was isolated from the extract of a solid culture of Aspergillus japonicus TPR–64 freshly isolated from soil. E–64 was obtained as white needles and the empirical formula was estimated to be C15N5–H27O5 (M. W. 357). This was almost neutral in its electrophoretic behavior and proved to be a specific and strong inhibitor toward thiol protease such as papain and cathepsin B. They combine equimolecularly and irreversibly.
View
NOBEL LECTURE: The Molecular Biology of Memory Storage: A Dialog Between Genes and Synapses
Article
  • Oct 2001
The biology of learning, and short-term and long-term memory, as revealed by Aplysia and other organisms, is reviewed.
View
View
View
Studies on thiol protease inhibitors. Part I. Isolation and characterization of E-64, a new thiol proteinase inhibitor
Article
  • Jan 1978
A new thiol protease inhibitor, named E-64, was isolated from the extract of a solid culture of Aspergillus japonicus TPR-64 freshly isolated from soil. E-64 was obtained as white needles and the empirical formula was estimated to be C15N5H27O5 (M. W. 357). This was almost neutral in its electrophoretic behavior and proved to be a specific and strong inhibitor toward thiol protease such as papain and cathepsin B. They combine equimolecularly and irreversibly.
View
Hyperactivation of Mitogen-Activated Protein Kinase Increases Phospho-Tau Immunoreactivity Within Human Neuroblastoma: Additive and Synergistic Influence of Alteration of Additional Kinase Activities
Article
  • Apr 1999
Mitogen-activated protein (MAP) kinase phosphorylates tau in cell-free analyses, but whether or not it does so within intact cells remains controversial. In the present study, microinjection of MAP kinase into SH-SY-5Y human neuroblastoma cells increased tau immunoreactivity toward the phosphodependent antibodies PHF-1 and AT-8. In contrast, treatment with a specific inhibitor of MAP kinase (PD98059) did not diminish “basal” levels of these immunoreactivities in otherwise untreated cells. These findings indicate that hyperactivation of MAP kinase increases phospho-tau levels within cells, despite that MAP kinase apparently does not substantially influence intracellular tau phosphorylation under normal conditions. These findings underscore that results obtained following inhibition of kinase activities do not necessarily provide an indication of the consequences accompanying hyperactivation of that same kinase. Several studies conducted in cell-free systems indicate that exposure of tau to multiple kinases can have synergistic effects on the nature and extent of tau phosphorylation. We therefore examined whether or not such effects could be demonstrated within these cells. Site-specific phospho-tau immunoreactivity was increased in additive and synergistic manners by treatment of injected cells with TPA (which activates PKC), calcium ionophore (which activates calcium-dependent kinases), and wortmannin (which inhibits PIP_3 kinase). Alteration in total tau levels was insufficient to account for the full extent of the increase in phospho-tau immunoreactivity. These additional results indicate that multiple kinase activities modulate the influence of MAP kinase on tau within intact cells.
View
Nuclear and cytosolic JNK signalling in neurons
Article
  • Apr 2014
It has been over 20 years since JUN amino-terminal kinases (JNKs) were identified as protein kinases that are strongly activated by cellular stress and that have a key role in apoptosis. Examination of Jnk-knockout mice and characterization of JNK behaviour in neuronal cells has further revealed the importance of the JNK family in the nervous system. As well as regulating neuronal death, JNKs govern brain morphogenesis and axodendritic architecture during development, and regulate important neuron-specific functions such as synaptic plasticity and memory formation. This Review examines the evidence that the spatial segregation of JNKs in neurons underlies their distinct functions and that compartment-specific targeting of JNKs may offer promising new therapeutic avenues for the treatment of diseases of the nervous system, such as stroke and neurodegenerative disorders.
View
Activity-Dependent p25 Generation Regulates Synaptic Plasticity and Aβ-Induced Cognitive Impairment
Article
  • Apr 2014
Cyclin-dependent kinase 5 regulates numerous neuronal functions with its activator, p35. Under neurotoxic conditions, p35 undergoes proteolytic cleavage to liberate p25, which has been implicated in various neurodegenerative diseases. Here, we show that p25 is generated following neuronal activity under physiological conditions in a GluN2B- and CaMKIIα-dependent manner. Moreover, we developed a knockin mouse model in which endogenous p35 is replaced with a calpain-resistant mutant p35 (Δp35KI) to prevent p25 generation. The Δp35KI mice exhibit impaired long-term depression and defective memory extinction, likely mediated through persistent GluA1 phosphorylation at Ser845. Finally, crossing the Δp35KI mice with the 5XFAD mouse model of Alzheimer's disease (AD) resulted in an amelioration of β-amyloid (Aβ)-induced synaptic depression and cognitive impairment. Together, these results reveal a physiological role of p25 production in synaptic plasticity and memory and provide new insights into the function of p25 in Aβ-associated neurotoxicity and AD-like pathology.
View